ATE235248T1 - Verfahren zur identifizierung und isolierung von einem molekül - Google Patents

Verfahren zur identifizierung und isolierung von einem molekül

Info

Publication number
ATE235248T1
ATE235248T1 AT00117699T AT00117699T ATE235248T1 AT E235248 T1 ATE235248 T1 AT E235248T1 AT 00117699 T AT00117699 T AT 00117699T AT 00117699 T AT00117699 T AT 00117699T AT E235248 T1 ATE235248 T1 AT E235248T1
Authority
AT
Austria
Prior art keywords
host cells
molecule
lysates
sample
binding partners
Prior art date
Application number
AT00117699T
Other languages
English (en)
Inventor
Michael Pfreundschuh
Hans-Georg Rammensee
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/580,980 external-priority patent/US6025191A/en
Priority claimed from US08/644,116 external-priority patent/US6140464A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE235248T1 publication Critical patent/ATE235248T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
AT00117699T 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül ATE235248T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/479,328 US5698396A (en) 1995-06-07 1995-06-07 Method for identifying auto-immunoreactive substances from a subject
US08/580,980 US6025191A (en) 1995-06-07 1996-01-03 Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
US08/644,116 US6140464A (en) 1995-06-07 1996-05-10 Nonapeptides that bind a HLA-A2.1 molecule

Publications (1)

Publication Number Publication Date
ATE235248T1 true ATE235248T1 (de) 2003-04-15

Family

ID=23903564

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00117699T ATE235248T1 (de) 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül
AT96919266T ATE222116T1 (de) 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül und von diesem erkannte moleküle

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96919266T ATE222116T1 (de) 1995-06-07 1996-06-07 Verfahren zur identifizierung und isolierung von einem molekül und von diesem erkannte moleküle

Country Status (11)

Country Link
US (2) US5698396A (de)
EP (1) EP0831879B1 (de)
JP (1) JP2002502354A (de)
CN (1) CN1136914C (de)
AT (2) ATE235248T1 (de)
CA (1) CA2223566C (de)
DE (2) DE69623014T2 (de)
DK (1) DK0831879T3 (de)
ES (1) ES2180782T3 (de)
PT (1) PT831879E (de)
WO (1) WO1996040209A1 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma
US20010053523A1 (en) * 1995-06-02 2001-12-20 M&E Biotech A/S. Method for identification of biologically active peptides and nucleic acids
DE69722176T2 (de) 1996-01-23 2004-03-18 The Board Of Trustees Of The Leland Stanford Junior University, Palo Alto Verfahren zur suche nach transdominanten effektorpeptiden und rna-molekülen
US6365344B1 (en) * 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6027916A (en) 1996-10-09 2000-02-22 Human Genome Sciences, Inc. Galectin 9 and 10SV Polynucleotides
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US6218521B1 (en) 1997-07-17 2001-04-17 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with gastric cancer and methods for diagnosing and treating gastric cancer
US6043084A (en) 1997-10-10 2000-03-28 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US6403373B1 (en) 1997-10-10 2002-06-11 Ludwig Institute For Cancer Research Isolated nucleic acid molecules associated with colon, renal, and stomach cancer and methods of using these
US20030138808A1 (en) * 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6140050A (en) * 1998-06-26 2000-10-31 Ludwig Institute For Cancer Research Methods for determining breast cancer and melanoma by assaying for a plurality of antigens associated therewith
US6440663B1 (en) 1998-10-05 2002-08-27 Ludwig Institute For Cancer Research Renal cancer associated antigens and uses therefor
JP2003527826A (ja) 1999-06-30 2003-09-24 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 癌関連抗原およびその使用
WO2001047959A2 (en) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
WO2001053349A2 (en) * 2000-01-21 2001-07-26 Ludwig Institute For Cancer Research Small cell lung cancer associated antigens and uses therefor
US6448073B1 (en) 2000-01-28 2002-09-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
DE60142615D1 (de) * 2000-04-28 2010-09-02 Mannkind Corp Epitop-synchronisierung in antigen präsentierenden zellen
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
US20030215425A1 (en) * 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
ES2295191T3 (es) * 2000-07-27 2008-04-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos de gsk3.
US20040086852A1 (en) * 2000-12-01 2004-05-06 Toshiro Ono Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
US8637305B2 (en) * 2001-11-07 2014-01-28 Mannkind Corporation Expression vectors encoding epitopes of target-associated antigens and methods for their design
EP1512014B1 (de) 2002-06-13 2009-08-05 MERCK PATENT GmbH Verfahren für die identifizierung von allo-antigenen und ihren verwendung für krebs therapie und transplantation
US8177823B2 (en) * 2005-06-30 2012-05-15 Depuy Spine Sarl Orthopedic clamping hook assembly
US8672732B2 (en) * 2006-01-19 2014-03-18 Schneider Electric It Corporation Cooling system and method
WO2008008541A2 (en) * 2006-07-14 2008-01-17 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
EP2129389B1 (de) 2007-02-15 2014-10-08 MannKind Corporation Verfahren zur verstärkung der t-zell-antwort
MX2009012635A (es) * 2007-05-23 2012-09-13 Mannkind Corp Vectores multicistronicos y metodos para su diseño.
AU2008314925B2 (en) 2007-10-25 2013-11-07 Toray Industries, Inc. Immune response inducer
BRPI0910509B8 (pt) 2008-07-10 2021-05-25 Toray Industries uso do anticorpo, anticorpo e composição farmacêutica
BRPI0911925B8 (pt) * 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
CN102112146B (zh) 2008-08-05 2014-03-12 东丽株式会社 免疫诱导剂
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8691510B2 (en) * 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
CN104195227B (zh) 2008-11-07 2017-04-12 适应生物技术公司 通过序列分析监测状况的方法
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2387627B1 (de) 2009-01-15 2016-03-30 Adaptive Biotechnologies Corporation Adaptive immunitätsprofilierung und verfahren zur erzeugung monoklonaler antikörper
CA2755734A1 (en) 2009-03-17 2010-09-23 Gaetan Otto Improved detection of gene expression
CN102459643B (zh) 2009-06-25 2016-06-01 弗雷德哈钦森癌症研究中心 检测获得性免疫的方法
AU2010310468A1 (en) 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
MX340015B (es) 2010-02-04 2016-06-22 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) 2010-02-04 2016-09-23 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
HUE025678T2 (en) 2010-02-04 2016-04-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
WO2012157737A1 (ja) 2011-05-19 2012-11-22 東レ株式会社 免疫誘導剤
DK2711015T3 (en) * 2011-05-19 2016-10-03 Toray Industries Immunity-inducing agent
PT2740793T (pt) 2011-08-04 2018-02-23 Toray Industries Composição de fármacos para o tratamento e/ou a prevenção de cancro
PT2740794T (pt) 2011-08-04 2018-06-14 Toray Industries Composição farmacêutica para o tratamento e/ou profilaxia de cancro
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
KR102041832B1 (ko) 2011-08-04 2019-11-08 도레이 카부시키가이샤 췌장암의 치료 및/또는 예방용 의약 조성물
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
JP6070191B2 (ja) 2011-08-04 2017-02-01 東レ株式会社 癌の治療及び／又は予防用医薬組成物
BR112014002616B1 (pt) 2011-08-04 2022-01-18 Toray Industries, Inc Método para detectar câncer pancreático
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
EP2768982A4 (de) 2011-10-21 2015-06-03 Adaptive Biotechnologies Corp Quantifizierung von adaptiven immunzellgenomen in einer komplexen mischung von zellen
US9824179B2 (en) 2011-12-09 2017-11-21 Adaptive Biotechnologies Corp. Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
BR112014021103A2 (pt) 2012-02-21 2019-10-15 Toray Industries, Inc Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
US9260513B2 (en) 2012-02-21 2016-02-16 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
PT2818483T (pt) 2012-02-21 2017-10-09 Toray Industries Composição medicinal para tratamento e/ou prevenção de cancro
HUE044611T2 (hu) 2012-02-21 2019-11-28 Toray Industries Gyógyászati készítmény rák kezelésére
DK2823060T3 (en) 2012-03-05 2018-05-28 Adaptive Biotechnologies Corp Determination of associated immune receptor chains from frequency-matched subunits
KR102155531B1 (ko) 2012-03-30 2020-09-15 도레이 카부시키가이샤 간암의 치료 및/또는 예방용 의약 조성물
PT2832366T (pt) 2012-03-30 2018-01-25 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar
CA2872468C (en) 2012-05-08 2020-10-27 Adaptive Biotechnologies Corporation Compositions and methods for measuring and calibrating amplification bias in multiplexed pcr reactions
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
RU2646466C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
JP6449160B2 (ja) 2012-10-01 2019-01-09 アダプティブ バイオテクノロジーズ コーポレイション 適応免疫受容体多様性およびクローン性特性決定による免疫能力評価関連出願の相互参照
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
WO2016175309A1 (ja) 2015-04-30 2016-11-03 東レ株式会社 免疫誘導剤
JP6862828B2 (ja) 2015-04-30 2021-04-21 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CN107619876A (zh) * 2017-11-01 2018-01-23 中国医学科学院药用植物研究所 一种箭叶淫羊藿与天平山淫羊藿的分子鉴定方法
CN107604092A (zh) * 2017-11-01 2018-01-19 中国医学科学院药用植物研究所 一种朝鲜淫羊藿与粗毛淫羊藿的分子鉴定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583024A (en) * 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
US5274087A (en) * 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
ATE270326T1 (de) * 1990-04-04 2004-07-15 Chiron Corp Protease von hepatitis-c-virus
AT401180B (de) * 1990-08-13 1996-07-25 Biomay Biotech Prod Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5405940A (en) * 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US5585464A (en) * 1993-02-19 1996-12-17 Theratech, Inc. Recombinant antigen for diagnosing rheumatoid arthritis
CN1118572A (zh) * 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
FR2705362B1 (fr) * 1993-05-18 1995-08-04 Agronomique Inst Nat Rech Clônage et expression du gêne de l'enzyme malolactique de Lactococcus lactis.
WO1995014772A1 (en) * 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
US5589579A (en) * 1994-07-19 1996-12-31 Cytoclonal Pharmaceutics, Inc. Gene sequence and probe for a marker of non-small cell lung carinoma

Also Published As

Publication number Publication date
EP0831879A4 (de) 2000-01-26
AU6165296A (en) 1996-12-30
EP0831879A1 (de) 1998-04-01
CN1136914C (zh) 2004-02-04
JP2002502354A (ja) 2002-01-22
DK0831879T3 (da) 2002-12-16
ES2180782T3 (es) 2003-02-16
DE69623014T2 (de) 2003-05-08
US5798264A (en) 1998-08-25
WO1996040209A1 (en) 1996-12-19
EP0831879B1 (de) 2002-08-14
CA2223566A1 (en) 1996-12-19
DE69627056D1 (de) 2003-04-30
PT831879E (pt) 2002-12-31
CN1190894A (zh) 1998-08-19
DE69623014D1 (de) 2002-09-19
CA2223566C (en) 2002-09-03
US5698396A (en) 1997-12-16
ATE222116T1 (de) 2002-08-15
AU704109B2 (en) 1999-04-15
DE69627056T2 (de) 2004-01-29

Similar Documents

Publication Publication Date Title
ATE235248T1 (de) Verfahren zur identifizierung und isolierung von einem molekül
DE59804008D1 (de) Verfahren zur identifikation von nucleinsäuren durch matrix-assistierte laser desorptions/ionisations massenspektrometrie
DE69632466D1 (de) Lösung die chaotropische mittel enthält und verwendung dieser lösung in verfahren zur isolierung von dna, rna und proteinen
ATE397092T1 (de) Methode zur direkten sequenzierung von nukleinsäuren
WO1998022589A3 (en) Survivin, a protein that inhibits cellular apoptosis, and its modulation
ATE295535T1 (de) Verfahren und vorrichtung zur analyse von geladenen molekülen durch isoelektrische fokussierung einer lösung
ATE503843T1 (de) Gesamt-chromosom analyse von protein-dns wechselwirkungen
ATE332505T1 (de) Verfahren und zusammensetzung zur auffindung von cervix-krebs
DE60228477D1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
DE69422339D1 (de) Verfahren zur Nachweis von Marijuana in einer Haar Probe
DE69618614D1 (de) NUKLEINSÄUREMOLEKÜLE MIT DER FÄHIGKEIT ZUR UNTERSCHEIDUNG VON PrPc UND PrPSc-PRIONPROTEIN-ISOFORMEN UND VERFAHREN ZU DEREN HERSTELLUNG
Swerdlow et al. Affinity of HMG17 for a mononucleosome is not influenced by the presence of ubiquitin-H2A semihistone but strongly depends on DNA fragment size
DE59408917D1 (de) Verfahren zur identifizierung von menschlichen und tierischen zellen mit der fähigkeit zu unbegrenzter proliferation oder zur tumorbildung
NO924912L (no) Fremgangsmaate ved paavisning av analyttvarianter, samt sett for utfoerelse av fremgangsmaaten
ATE474922T1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
ATE509946T1 (de) Fluoreszenzproteine und chromoproteine aus nicht- aequorea-hydrozoa-spezies sowie verfahren zur verwendung davon
ATE278964T1 (de) Verfahren zur proteinextraktion
DE69927691D1 (de) Verfahren zur eiweissanalyse
Egyházi et al. Phosphorylation of some chromosomal nonhistone proteins in active genes is blocked by the transcription inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB).
ATE405592T1 (de) Verfahren zur bildung eines protein- mikroarraysystems
WO2001016170A3 (en) Card proteins involved in cell death regulation
EA199800843A1 (ru) Компьютерный способ создания химических структур, имеющих общие функциональные характеристики
ATE306671T1 (de) Massenfingerabdrucken und seiner verwendung zur identifizierung von protein-affinitätsliganden
WO1998024902A8 (en) Adaptor protein frs2 and related products and methods
DE60233347D1 (de) Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties